West Nile virus. Primer for family physicians.
Authors:
- Russell D MacDonaldRMRussell D MacDonald
- Valerie F KrymVKValerie F Krym
- 1 June 2005
- journal article
- review article
- Vol. 51 (6) , 833-7
Abstract
To provide primary care physicians with an understanding of West Nile virus in North America. This article focuses on epidemiology, clinical features, diagnosis, and prevention of infection. MEDLINE and EMBASE searches revealed epidemiologic, surveillance, cohort, and outcome studies providing level II evidence. There were no randomized controlled trials of treatment. Recommended prevention and treatment strategies are based on level II and III evidence. The mosquito-borne virus that first appeared on this continent in 1999 is now prevalent throughout North America. Most infections are asymptomatic. Fewer than 1% of those infected develop severe illness; 3% to 15% of those with severe illness die. While methods for controlling the mosquito population are available, we lack evidence that they reduce infection in the general human population. Family physicians have an important role in advising their patients on ways to prevent infection and in identifying patients who might be infected with West Nile virus. The general population is at low risk of West Nile virus infection. Prevention of infection rests on controlling the mosquito population and educating people on how to protect themselves against mosquito bites.Keywords
This publication has 26 references indexed in Scilit:
- West Nile virusThe Lancet Infectious Diseases, 2002
- Human Exposures to N, N-diethyl-m-toluamide Insect Repellents Reported to the American Association of Poison Control Centers 1993–1997International Journal of Toxicology, 2002
- Use of Immunoglobulin M Cross-Reactions in Differential Diagnosis of Human Flaviviral Encephalitis Infections in the United StatesClinical and Vaccine Immunology, 2002
- Short report: absence of protective neutralizng antibodies to West Nile virus in subjects following vaccination with Japanese encephalitis or dengue vaccines.The American Journal of Tropical Medicine and Hygiene, 2002
- Human surveillance for West Nile virus infection in Ontario in 2000.2002
- Efficacy of Interferon α-2b and Ribavirin against West Nile Virus In VitroEmerging Infectious Diseases, 2002
- Potential North American Vectors of West Nile VirusAnnals of the New York Academy of Sciences, 2001
- Yellow fever vector live-virus vaccines: West Nile virus vaccine developmentTrends in Molecular Medicine, 2001
- Dead Crow Densities and Human Cases of West Nile Virus, New York State, 2000Emerging Infectious Diseases, 2001
- Clinical Findings of West Nile Virus Infection in Hospitalized Patients, New York and New Jersey, 2000Emerging Infectious Diseases, 2001